Global Sustained-release Medicine Market Growth (Status and Outlook) 2023-2029

Global Sustained-release Medicine Market Growth (Status and Outlook) 2023-2029

The global Sustained-release Medicine market size is projected to grow from US$ 34090 million in 2022 to US$ 55270 million in 2029; it is expected to grow at a CAGR of 7.1% from 2023 to 2029.

The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.

Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.

Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D

LPI (LP Information)' newest research report, the “Sustained-release Medicine Industry Forecast” looks at past sales and reviews total world Sustained-release Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Sustained-release Medicine sales for 2023 through 2029. With Sustained-release Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sustained-release Medicine industry.

This Insight Report provides a comprehensive analysis of the global Sustained-release Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sustained-release Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sustained-release Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sustained-release Medicine and breaks down the forecast by type, by distribution channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sustained-release Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Sustained-release Medicine market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Original Ground Medicine
Generic Medicine

Segmentation by distribution channel
Hospital
Drugstore
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane

Please note: The report will take approximately 2 business days to prepare and deliver.